



Occupational  
Cancer  
Research  
Centre

# An Evaluation of Glyphosate Use and the Risk of Non-Hodgkin Lymphoma Major Histological Sub-Types in the North American Pooled Project

Manisha Pahwa, John J. Spinelli, Laura Beane Freeman, Paul A. Demers, Aaron Blair, Punam Pahwa, James A. Dosman, John R. McLaughlin, Shelia Hoar Zahm, Kenneth P. Cantor, Dennis D. Weisenburger, Shelley A. Harris

International Society for Environmental Epidemiology Conference | Sao Paulo, Brazil | August 31, 2015

#868 (Pesticides and Other POPs)

**Towards** a cancer-free workplace

Dewayne Johnson v.  
Monsanto Company

Defendant's Exhibit 2851

Case No: CGC-16-550128

# Disclosure of Competing Financial Interests



None

# IARC Evaluation of Glyphosate



- Limited evidence of NHL in humans and sufficient evidence of cancer in animals
- Mechanistic evidence of genotoxicity and oxidative stress
- Classified as Group 2A (probably carcinogenic)

## Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate

In March, 2015, 17 experts from 11 countries met at the International Agency for Research on Cancer (IARC; Lyon, France) to assess the carcinogenicity of the organophosphate pesticides tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate (table). These assessments will be published as volume 112 of the IARC Monographs.<sup>1</sup>

The insecticides tetrachlorvinphos

to the bioactive metabolite, paraoxon, is similar across species. Although bacterial mutagenesis tests were negative, parathion induced DNA and chromosomal damage in human cells in vitro. Parathion markedly increased rat mammary gland terminal end bud density.<sup>4</sup> Parathion use has been severely restricted since the 1980s.

The insecticides malathion and diazinon were classified as "probably

aggressive cancers after adjustment for other pesticides.<sup>9</sup> In mice, malathion increased hepatocellular adenoma or carcinoma (combined).<sup>10</sup> In rats, it increased thyroid carcinoma in males, hepatocellular adenoma or carcinoma (combined) in females, and mammary gland adenocarcinoma after subcutaneous injection in females.<sup>4</sup> Malathion is rapidly absorbed and distributed. Metabolism to the



Lancet Oncol 2015

Published Online

March 20, 2015

<http://dx.doi.org/10.1016/>


**Towards a cancer-free workplace**



International Survey of Herbicide Resistant Weeds: <http://weedsociety.org/graphs/geochart.aspx>

**Towards a cancer-free workplace**

# North American Pooled Project



# General Design of Case-Control Studies



**INCIDENT CASES**




Cancer registries,  
hospitals



**POPULATION-BASED  
CONTROLS**



Telephone lists, voters'  
lists, health insurance  
records, mortality records



**QUESTIONNAIRE**  
(in person, phone, mail)

**Towards** a cancer-free workplace

# Glyphosate Use Information



	<b>EVER/NEVER</b>	<b>DURATION</b> # Years	<b>FREQUENCY</b> # Days/Year	<b>LIFETIME DAYS</b> # Years x # Days/Year
Iowa/Minnesota	✓	✓	X	X
Kansas	✓	X	X	X
Nebraska	✓	✓	✓	✓
Canada	✓	✓	✓	✓

Towards a cancer-free workplace

# Conceptual Framework for Analysis



## Glyphosate Use

Ever/Never  
Duration  
Frequency  
Lifetime days

## NHL Risk

Overall  
FL  
DLBCL  
SLL  
Other



## Covariates

Age, sex, state/province,  
lymphatic/hematopoietic cancer in a first-  
degree relative, proxy respondent use, any  
PPE use; *2,4-D, dicamba, malathion use*



Towards a cancer-free workplace

# Selected Characteristics of NHL Cases and Controls



Variable	Cases (N)	Controls (N)	OR* (95% CI)
<b>N</b>	1690	5131	
<b><i>Histological sub-type</i></b>			
Follicular (FL)	468		
Diffuse (DLBCL)	647		
Small lymphocytic (SLL)	171		
Other	404		
<b><i>Location</i></b>			
U.S.	1177	3625	
Canada	513	1506	
<b><i>Respondent type</i></b>			
Self	1140	3372	1
Proxy	533	1692	1.01 (0.89, 1.15)
Unknown/missing	17	67	
<b><i>Lymphatic or hematopoietic cancer in a first-degree relative</i></b>			
No	1493	4790	1
Yes	139	202	2.13 (1.69, 2.67)
Unknown/missing	58	139	

\*ORs adjusted for age and location

Towards a cancer-free workplace

# Glyphosate Use and NHL Risks



NHL sub-type	Number of cases who reportedly ever used glyphosate	OR <sup>a</sup> (95% CI)	OR <sup>b</sup> (95% CI)
Overall	113	1.43 (1.11, 1.83)	1.13 (0.84, 1.51)
FL	28	1.00 (0.65, 1.54)	0.69 (0.41, 1.15)
DLBCL	45	1.60 (1.12, 2.29)	1.23 (0.81, 1.88)
SLL	15	1.77 (0.98, 3.22)	1.79 (0.87, 3.69)
Other	25	1.66 (1.04, 2.63)	1.51 (0.87, 2.60)

a. ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of a proxy respondent, use of any personal protective equipment; b. ORs adjusted for all covariates in model (a) plus use of 2,4-D, use of dicamba, use of malathion

Towards a cancer-free workplace

# Duration (#Years) of Glyphosate Use and NHL Risks



# years	OR* (95% CI)				
	Overall	FL	DLBCL	SLL	Other
0	1	1	1	1	1
>0 and ≤3.5	1.59 (1.13, 2.22)	0.95 (0.52, 1.74)	2.02 (1.28, 3.21)	1.49 (0.63, 3.58)	2.08 (1.14, 3.78)
>3.5	1.20 (0.82, 1.75)	0.88 (0.46, 1.71)	1.19 (0.67, 2.12)	1.98 (0.89, 4.39)	1.32 (0.64, 2.71)
P-trend	0.03	0.96	0.03	0.08	0.14

\*ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of a proxy respondent, use of any personal protective equipment

Towards a cancer-free workplace

# Frequency (#Days/Year) of Glyphosate Handling and NHL Risks



# days/year handled	OR* (95% CI)				
	Overall	FL	DLBCL	SLL	Other
0	1	1	1	1	1
>0 and ≤2	1.03 (0.67, 1.60)	0.81 (0.35, 1.84)	0.95 (0.49, 1.81)	1.27 (0.42, 3.89)	1.49 (0.66, 3.32)
>2	<b>2.42</b> <b>(1.48, 3.96)</b>	2.21 (0.99, 4.93)	<b>2.83</b> <b>(1.48, 5.41)</b>	2.29 (0.66, 7.98)	2.26 (0.85, 5.99)
P-trend	<b>0.02</b>	0.07	<b>0.04</b>	0.21	0.85

\*ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of a proxy respondent, use of any personal protective equipment

Towards a cancer-free workplace

# Lifetime Days (#Years x #Days/Year) of Glyphosate Use and NHL Risks



Lifetime days	OR* (95% CI)				
	Overall	FL	DLBCL	SLL	Other
0	1	1	1	1	1
>0 and ≤7	1.20 (0.74, 1.95)	1.03 (0.43, 2.48)	1.14 (0.56, 2.30)	1.04 (0.24, 4.58)	1.93 (0.82, 4.51)
>7	1.55 (0.99, 2.44)	1.33 (0.60, 2.94)	1.51 (0.79, 2.88)	2.13 (0.76, 5.96)	1.69 (0.68, 4.15)
P-trend	0.02	0.02	0.10	0.01	0.33

\*ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of a proxy respondent, use of any personal protective equipment

Towards a cancer-free workplace

# Challenges



- Uncollected information about duration and frequency of glyphosate use in some locations
- Small numbers for certain stratified analyses
- Measurement error
- Potential recall bias and unmeasured confounding

# Strengths



- Larger sample size = more statistical power to incorporate evaluations of NHL sub-types with detailed glyphosate use metrics
- Risk estimates adjusted for other pesticide uses *(results not presented)*
- Evaluated ORs based on data from self-respondents only and assessed effect modification of PPE use on glyphosate-NHL associations *(results not presented)*

# Conclusions



- Glyphosate use may be associated with ↑ risk of NHL
- Some differences in risk by sub-type, but not consistent across different glyphosate use metrics
- Large sample size yielded more precise results than possible in previous smaller studies



# Further Considerations



- Glyphosate use is projected to increase worldwide, especially in emerging large-scale agricultural economies in Latin America, Asia, and South Africa
- Use of glyphosate is important for global food supply

## ***BUT...***

- Glyphosate-resistant weeds are a concern and threat to its prolonged and isolated use
- The human (and environmental) health effects of newer herbicide formulations that contain glyphosate with  $\geq 1$  other active ingredient are largely unknown

# Acknowledgements



- **Canadian investigators:** Drs. Shelley A. Harris, John J. Spinelli, Paul A. Demers, Punam Pahwa, James A. Dosman, John R. McLaughlin
- **U.S. investigators:** Drs. Laura Beane Freeman, Aaron Blair, Shelia Hoar Zahm, Kenneth P. Cantor, Dennis D. Weisenburger
- **NAPP Executive Committee:** Drs. Shelley A. Harris, Laura Beane Freeman, John J. Spinelli
- **Data pooling:** Mr. Joe Barker (IMS Inc.)

*This analysis was funded by the Canadian Cancer Society Research Institute  
(Prevention Research Grant #703055)*

**Towards** a cancer-free workplace

# Contact



Manisha Pahwa, Research Associate  
Occupational Cancer Research Centre, Cancer Care Ontario  
620 University Avenue, Toronto, Ontario, M5G 2L7  
[manisha.pahwa@occupationalcancer.ca](mailto:manisha.pahwa@occupationalcancer.ca)  
[www.occupationalcancer.ca](http://www.occupationalcancer.ca)

**Towards** a cancer-free workplace



# **Towards** a cancer free workplace

[www.occupationalcancer.ca](http://www.occupationalcancer.ca)

**Towards** a cancer-free workplace

# About NHL and Glyphosate



## NHL

- A cancer that starts in the lymphocytes
- Heterogeneous, according to type of cell affected

## Glyphosate


- A broad-spectrum herbicide
- Commonly known as “Roundup”
- The most frequently used herbicide in the world



Towards a cancer-free workplace

# Estimated Agricultural Use for Glyphosate, 2012

EPest-Low



Estimated use on agricultural land, in pounds per square mile

- < 4.52
- 4.52 - 21.12
- 21.13 - 88.06
- > 88.06

No estimated use

Source: U.S. Geological Survey. 2012 Pesticide Use Maps.

[https://water.usgs.gov/nawqa/pnsp/usage/maps/show\\_map.php?year=2012&map=GLYPHOSATE&hilo=L](https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2012&map=GLYPHOSATE&hilo=L)



# Proxy Respondent Analysis



## Glyphosate Use

Ever/Never  
Duration  
Frequency  
Lifetime days

## NHL Risk

Overall  
FL  
DLBCL  
SLL  
Other

*Proxy and self-respondents*  
*Self-respondents only*

Age, sex, state/province,  
lymphatic/hematopoietic cancer in a first-  
degree relative, use of any PPE, use of  
2,4-D, use of dicamba, use of malathion

## Covariates

**Towards** a cancer-free workplace

# Selected Characteristics of NHL Cases and Controls (Continued)



Variable	Cases (N)	Controls (N)	OR (95% CI)
<b><i>Ever lived or worked on a farm or ranch</i></b>			
No	577	1840	1
Yes	1102	3276	1.06 (0.94, 1.20)
Unknown/missing	11	15	
<b><i>Ever used any type of PPE</i></b>			
No	374	1127	1
Yes	105	310	1.12 (0.86, 1.45)
Unknown/missing	1211	3694	

Towards a cancer-free workplace

# Proxy vs. Self Respondents



## OR (95% CI) for NHL Overall

Glyphosate Use	Proxy and Self Respondents <sup>a</sup>	Self Respondents Only <sup>b</sup>
Never used	1	1
Ever used	1.13 (0.84, 1.51)	0.95 (0.69, 1.32)
<b>Duration (# years)</b>		
>0 and ≤3.5	1.28 (0.88, 1.84)	1.17 (0.79, 1.74)
>3.5	0.94 (0.62, 1.42)	0.78 (0.49, 1.24)
<b>Frequency (# days/year)</b>		
>0 and ≤2	0.74 (0.46, 1.19)	0.66 (0.39, 1.12)
>2	<b>1.73 (1.02, 2.94)</b>	<b>1.77 (0.99, 3.17)</b>
<b>Lifetime days (# years x # days/year)</b>		
0 and ≤7	0.87 (0.52, 1.45)	0.82 (0.46, 1.44)
>7	1.08 (0.66, 1.77)	1.06 (0.62, 1.81)

a. ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of a proxy respondent, use of any PPE, use of 2,4-D, use of dicamba, use of malathion; b. ORs adjusted for age, sex, state/province, lymphatic or hematopoietic cancer in a first-degree relative, use of any PPE, use of 2,4-D, use of dicamba, use of malathion

# Future Research Priorities



- Evaluation of other agricultural exposures, confounding, and interactions
- Non-occupational exposures
- Factors that modify exposure, e.g. immune conditions

**Towards** a cancer-free workplace

# Acknowledgements



## Canadian investigators

- Shelley A. Harris
- John J. Spinelli
- Paul A. Demers
- Punam Pahwa
- James A. Dosman
- John R. McLaughlin

## U.S. investigators

- Laura Beane Freeman
- Aaron Blair
- Shelia Hoar Zahm
- Kenneth P. Cantor
- Dennis D. Weisenburger



Towards a cancer-free workplace